Study on the invitro synergistic susceptibility and biofilm inhibition mechanism of ceftazidime-avibactam combined with aztreonam against carbapenem-resistant Klebsiella pneumoniae
ObjectiveThis study aims to investigate the synergistic effects and biofilm inhibition mechanisms of ceftazidime-avibactam (CZA) combined with aztreonam (ATM) against carbapenem-resistant Klebsiella pneumonia (CRKP) commonly found in the local clinical setting, providing new insights for clinical an...
Saved in:
| Main Authors: | Guangfen Wang, Hui Zhang, Qiaoping Wu, Jianqiang Xu, Xuedan Qiu, Jinyuan Chen, Fujie Cui, Jian Zhou, Qingcao Li |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-03-01
|
| Series: | Frontiers in Microbiology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmicb.2025.1542029/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
In vitro activity of aztreonam–avibactam combination against blood culture isolates of Stenotrophomonas maltophilia in Japan before the launch of ceftazidime–avibactam
by: Wataru Aoki, et al.
Published: (2025-05-01) -
Aztreonam Acts as a Synergist for Ceftazidime/Avibactam Against Carbapenem-Resistant Enterobacteriaceae (CRE) of Various Carbapenemase Phenotypes in Southwestern China
by: Ruan X, et al.
Published: (2025-05-01) -
Carbapenem-resistant Klebsiella pneumoniae infections in Chinese children: in vitro activities of ceftazidime-avibactam and aztreonam-avibactam against carbapenemase-producing strains in a two-center study
by: Xia Ran, et al.
Published: (2025-03-01) -
Risk factors for mortality in patients treated with ceftazidime-avibactam for ceftazidime-avibactam susceptible carbapenem-resistant Klebsiella pneumoniae bacteremia
by: Yi-Tsung Lin, et al.
Published: (2025-09-01) -
In Vitro Activity of Aztreonam-avibactam and Comparator Agents Against Carbapenemase-producing Enterobacterales Collected in Turkey and the Middle East as Part of the ATLAS Surveillance Program: 2018-2022
by: Mark Estabrook, et al.
Published: (2024-12-01)